# V56 Queue: Progression-Therapy Opportunity Audit

Status: in-progress

V56 is a three-hour active research block aimed at a better treatment for MS
progression. It cannot guarantee a cure or therapeutic result. Its obligation
is to maximize the chance of useful progress without manufacturing one: a route
advances only if progression-relevant human evidence, intervention direction,
and a concrete validation path all survive scrutiny.

## Timing

- Block start UTC: 2026-08-05T21:03:56Z
- Active target: 3h cumulative active time
- Projected target UTC if this interval stays continuous: 2026-08-06T00:03:56Z
- Active session intervals:
  - 2026-08-05T21:03:56Z - OPEN
- Cumulative completed active runtime: 0h00m00s
- Wall-clock span: open

## Boundaries And Environment

- OpenGWAS: **EXPIRED / HTTP 401**. The locally decoded expiry is
  2026-07-24 08:00 UTC. No OpenGWAS-dependent result may be generated until a
  human renews the token; route around it and never treat 401 as a null.
- SAP AI Core key: present. Models may propose or criticize; model output is
  never biological evidence.
- V41 discovery-exhaustion boundary remains in force. V56 performs targeted
  therapeutic re-examination and data/source scouting, not an unconstrained
  public-data signal hunt.
- V54 established no progression biomarker, causal mechanism, target,
  treatment effect, or means of halting MS. V56 starts from that null boundary.
- Predicted structure and external literature remain explicitly classed
  context, not project-grounded evidence.
- Locked rules and preregistrations are immutable; quarantined data remain
  unread.

## Fixed Decision Rule

A therapeutic route can enter a future-validation shortlist only if it has:

1. progression-relevant human evidence rather than relapse-only or generic
   inflammatory association;
2. a directionally specified intervention consistent with the human signal;
3. plausible compartment exposure and selectivity;
4. a concrete falsifiable next test with obtainable data or experiment; and
5. no unresolved source, batch, composition, multiplicity, or target-identity
   failure that invalidates the claim.

Failing any gate produces a documented no-go or data requirement, not a rescue.

## Backlog

| item | status | note |
|---|---|---|
| Opening health, evidence-boundary, and strategic audit | done | Clean/aligned start; OpenGWAS expired and routed around; five-gate route rule frozen before analysis. |
| Progression-treatment opportunity map | todo | Catalogue plausible route families against the five fixed gates using committed V52-V54 evidence. |
| Current primary-source therapeutic landscape scan | todo | Check current trial/regulatory/publication evidence for progression-modifying mechanisms; external context only. |
| New progression-data availability scout | in-progress | Found GSE247181 rapid/slow untreated SPMS PBMC and GSE264094/GSE281805 BRL spatial transcriptomics; both frozen before testing. Continue source audit. |
| External-source provenance records | todo | Class every integrated source and keep it outside grounded trees; run provenance gate. |
| GSE281805 processed BRL module bridge test | done | Four modules pass frozen BRL-vs-mixed gate, but none passes post-result common-slide max-T sensitivity; overall route interpretation inconclusive. 30,000-family null calibration 0.0514, excess p=0.1303. |
| GSE281805 raw matched-NAWM reconstruction | blocked | Calibration failed: 84/117 source AOIs, median rho 0.8555, minimum module rho 0.2516, 3/4 key signs. Biological test correctly not run. Needs author filtered manifest/intermediate matrix. |
| GSE247181 rapid/slow SPMS PBMC module test | in-progress | Frozen plan exists; acquire/process Clariom D CEL data or locate an authoritative processed matrix without changing the plan. |
| Direction and modality fail-fast audit | todo | Verify that any route's required activation/inhibition, compartment, exposure, and collateral-function profile are coherent. |
| Multi-lineage adversarial review | todo | Ask Claude and Gemini for the strongest fatal weakness and decisive test; ground concrete suggestions only. |
| Progression-therapy synthesis | todo | Write the honest ranked verdict: advance / data-gated / no-go, with exact next action and no therapeutic inflation. |
| Full verification, RAG rebuild, push, and run summary | todo | Gates, guards, clean tree, remote push, exact active-time close. |

## Per-Iteration Notes

- 2026-08-05T21:03:56Z: V56 began from a clean, synchronized repository.
  The fixed constraint is that no route advances without progression-relevant
  human evidence, intervention direction, and a concrete validation path.
- 2026-08-05: Environment check found SAP AI Core configured and OpenGWAS
  expired (HTTP 401; decoded expiry 2026-07-24 08:00 UTC). Genetics API work is
  routed around pending human renewal.
- 2026-08-05T21:33Z: Targeted scouting found two public progression-relevant
  packages absent from the V54 inventory. GSE281805/GSE264094 provides 17-donor
  CD68-enriched lesion/NAWM GeoMx data tied to a rapid-progression lesion
  phenotype; GSE247181 provides 10 rapid and 10 slow untreated SPMS PBMC
  profiles. Plans were frozen before expression testing.
- 2026-08-05T21:33Z: The processed GSE281805 donor-level test gave frozen
  max-T passes for CD44/CXCR4, MIF, lysosomal, and resolution/efferocytosis
  modules. An acquisition audit then found early slides with BRL but no mixed
  rim. On the four common slides, no module retained max-T significance
  (lysosomal p=0.0524; resolution p=0.0619; CD44/CXCR4 p=0.1524). This is an
  inconclusive progression-adjacent association, not a target or treatment
  result. Raw matched-NAWM reconstruction is the next decisive internal task.
- 2026-08-05T21:52Z: The exact `standR` 1.16.0 processing stack was installed
  and the authors' scripts were audited. Their fixed path is segment/probe QC,
  TMM, 300 negative-control genes, and RUV4 k=5 preserving lesion class. The
  public deposit omits ROI area/nuclei and the final filtered sample worksheet;
  a calibration-gated raw sensitivity plan was frozen before NAWM scoring, and
  this omission prevents any raw sensitivity from independently advancing a
  route.
- 2026-08-05T22:10Z: The corrected official-package reconstruction failed the
  frozen calibration: 138/296 AOIs survived reconstructible LOQ QC versus 211
  implied by the author table; only 84/117 source AOIs were comparable, median
  sample rho was 0.8555, minimum module rho 0.2516, and CD44/CXCR4 reversed
  sign. The matched-NAWM biological test was not run. This is a reproducibility
  block, not a biological null; exact author filtered/intermediate data are
  required. Work moved to GSE247181.
